» Go to news main
Just published! Systematic Review of Diffuse Hemispheric Glioma, H3 G34‑mutant: Outcomes and Associated Clinical Factors
Posted by Angie Kinsman on
August 19, 2022
in
Pediatrics
Dr. Daddy Mata-Mbemba has published a new article!
Systematic Review of Diffuse Hemispheric Glioma, H3 G34-mutant: Outcomes and Associated Clinical Factors
Cameron Crowell, Daddy Mata-Mbemba, Julie Bennett, Kara Matheson, Michael Mackley, Sébastien Perreault, Craig Erker
Published in Neuro-Oncology Advances, August 2022.
"A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival and prognostic features is paramount for clinical advancements and patient care. ..." Read more.
Recent News
- Just published! Surgical or Endovascular Treatment of MCA Aneurysms: An Agreement Study
- Just published! Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion: A clinical practice guideline
- Just published! Preparedness of Residents and Medical Students for the Transition to Competence by Design in Diagnostic Radiology Post‑Graduate Medical Education
- Just published! Systematic Review of Diffuse Hemispheric Glioma, H3 G34‑mutant: Outcomes and Associated Clinical Factors
- Just published! Inaugural Pan‑Canadian RADGames: Results From a Successful Approach to Radiology Education for Medical Students
- Just published! Canadian Association of Radiologists Prostate MRI White Paper
- Publication: Screening Criteria Evaluation for Expansion in Pulmonary Neoplasias (SCREEN)
- Publication: MR Imaging of Pediatric Low‑Grade Gliomas: Pretherapeutic Differentiation of BRAF V600E Mutation, BRAF Fusion, and Wild‑Type Tumors in Patients without Neurofibromatosis‑1
Comments
All comments require a name and email address. You may also choose to log-in using your preferred social network or register with Disqus, the software we use for our commenting system. Join the conversation, but keep it clean, stay on the topic and be brief.
Read comments policy.
comments powered by Disqus